Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to go after cancer cells. It’s the latest deal in the field of cancer drug developers aiming for off-the-shelf treatments intended to be easier and less expensive to manufacture, distribute, and administer compared to earlier cell therapies.
MedCity News
How digital health impacts the development and adoption of cancer immunotherapies
Shares1
Essential to the future of cancer immunotherapies is a digital health infrastructure that can support reliable, secure and compliant data collection from disparate systems and devices. As more and more immuno-oncology (IO) treatments come to market, biopharma will require data to enable more efficient research and development; providers will require data to drive more personalized treatments and payers will require data that enables them to make informed decisions about which therapies to cover.
There are new data-related challenges as well. Far more data are becoming available to oncologists, caregivers, insurers, biopharma companies, and other stakeholders, making it more difficult to parse the data that are actionable and valuable. IO combination therapies are gaining approval for the treatment of a wide variety of conditions.